. 2022 Dec 6;23(1):194–206. doi: 10.5230/jgc.2023.23.e1

Table 1. Patterns of gastric cancer recurrence after curative resection.

Study	Design	Year	Geographic region	Stage	No	Operation	Adjuvant treatment	Local^*	Regional^*	Peritoneal metastasis^*	Hematogenous metastasis^*
Smalley et al. [32]	RCT	2012	U.S.	≥T3 or N+	227	D0–1	Not used	8.0%	39.0%		18.0%
Smalley et al. [32]	RCT	2012	U.S.	≥T3 or N+	282	D0–1	CCRT	2.0%	22.0%		16.0%
Songun et al. [30]	RCT	2010	Dutch	I–III	380	D1	Not used	21.6%	19.2%	34.2%
Songun et al. [30]	RCT	2010	Dutch	I–III	330	D2	Not used	12.1%	13.0%	29.7%
Conrad et al. [33]	Retrospective	2016	Canada	≥T3 or N+	197	N.D.	CCRT	7.1%		28.9%
Sakuramoto et al. [29]	RCT	2007	Japan	≥T2 or N+	530	R0/D2	Not used	2.8%	8.7%	15.8%	11.3%
Sakuramoto et al. [29]	RCT	2007	Japan	≥T2 or N+	529	R0/D2	Chemotherapy	1.3%	5.1%	11.2%	10.2%
Bang et al. [31]	RCT	2012	Korea	≥T2 or N+	515	R0/D2	Not used	8.5%		10.9%	15.1%
Bang et al. [31]	RCT	2012	Korea	≥T2 or N+	520	R0/D2	Chemotherapy	4.0%		9.0%	9.4%
Yu et al. [28]	RCT	2015	Korea	≥T2 or N+	228	R0/D2	Chemotherapy	4.8%	12.7%	16.2%	8.3%
Yu et al. [28]	RCT	2015	Korea	≥T2 or N+	230	R0/D2	CCRT	4.8%	6.5%	16.1%	7.0%
Chang et al. [26]	Retrospective	2012	Korea	III	382	R0/D2	Chemotherapy	9.7%	27.5%	40.6%	23.8%
Pachaury et al. [34]	Retrospective	2022	India	N3	196	R0/D2	Chemotherapy or CCRT	All LRR 21.9%		30.6%	20.9%
Pachaury et al. [34]	Retrospective	2022	India	N3	196	R0/D2	Chemotherapy or CCRT	LRR only 10.7%		30.6%	20.9%

RCT = randomized controlled trial; CCRT = concurrent chemoradiotherapy; N.D. = not documented; LRR = locoregional recurrence.

^*Cases of local and regional, peritoneal and regional, or peritoneal and hematogenous recurrence were reported together without distinction, were summed up, and presented in this table.